These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25255039)

  • 1. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
    Merk D; Lamers C; Ahmad K; Carrasco Gomez R; Schneider G; Steinhilber D; Schubert-Zsilavecz M
    J Med Chem; 2014 Oct; 57(19):8035-55. PubMed ID: 25255039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).
    Merk D; Gabler M; Gomez RC; Flesch D; Hanke T; Kaiser A; Lamers C; Werz O; Schneider G; Schubert-Zsilavecz M
    Bioorg Med Chem; 2014 Apr; 22(8):2447-60. PubMed ID: 24685112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.
    Merk D; Lamers C; Weber J; Flesch D; Gabler M; Proschak E; Schubert-Zsilavecz M
    Bioorg Med Chem; 2015 Feb; 23(3):499-514. PubMed ID: 25583100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
    Flesch D; Gabler M; Lill A; Gomez RC; Steri R; Schneider G; Stark H; Schubert-Zsilavecz M; Merk D
    Bioorg Med Chem; 2015 Jul; 23(13):3490-8. PubMed ID: 25934227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the relationship of anthranilic derivatives structure and the FXR (Farnesoid X receptor) agonist activity.
    Kronenberger T; Windshügel B; Wrenger C; Honorio KM; Maltarollo VG
    J Biomol Struct Dyn; 2018 Dec; 36(16):4378-4391. PubMed ID: 29237358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Investigation for Optimization of Anthranilic Acid Derivatives as Partial FXR Agonists by in Silico Approaches.
    Chen M; Yang X; Lai X; Kang J; Gan H; Gao Y
    Int J Mol Sci; 2016 Apr; 17(4):536. PubMed ID: 27070594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesoid X receptor: from medicinal chemistry to clinical applications.
    Fiorucci S; Mencarelli A; Distrutti E; Zampella A
    Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
    Luan ZL; Huo XK; Dong PP; Tian XG; Sun CP; Lv X; Feng L; Ning J; Wang C; Zhang BJ; Ma XC
    Eur J Med Chem; 2019 Nov; 182():111652. PubMed ID: 31494470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure-activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism.
    Gohda K; Iguchi Y; Masuda A; Fujimori K; Yamashita Y; Teno N
    Bioorg Med Chem Lett; 2021 Jun; 41():128026. PubMed ID: 33839252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
    Luo G; Lin X; Li Z; Xiao M; Li X; Zhang D; Xiang H
    Eur J Med Chem; 2021 Jan; 209():112910. PubMed ID: 33049605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist.
    Hu L; Ren Q; Deng L; Zhou Z; Cai Z; Wang B; Li Z
    Eur J Med Chem; 2021 Feb; 211():113106. PubMed ID: 33360559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
    Tully DC; Rucker PV; Chianelli D; Williams J; Vidal A; Alper PB; Mutnick D; Bursulaya B; Schmeits J; Wu X; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Seidel HM; Molteni V; Liu B; Phimister A; Joseph SB; Laffitte B
    J Med Chem; 2017 Dec; 60(24):9960-9973. PubMed ID: 29148806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.
    Wang L; Si P; Sheng Y; Chen Y; Wan P; Shen X; Tang Y; Chen L; Li W
    Chem Biol Drug Des; 2015 Apr; 85(4):481-7. PubMed ID: 25228339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonacidic Farnesoid X Receptor Modulators.
    Flesch D; Cheung SY; Schmidt J; Gabler M; Heitel P; Kramer J; Kaiser A; Hartmann M; Lindner M; Lüddens-Dämgen K; Heering J; Lamers C; Lüddens H; Wurglics M; Proschak E; Schubert-Zsilavecz M; Merk D
    J Med Chem; 2017 Aug; 60(16):7199-7205. PubMed ID: 28749691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators.
    Schierle S; Schmidt J; Kaiser A; Merk D
    ChemMedChem; 2018 Dec; 13(23):2530-2545. PubMed ID: 30353976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands.
    Di Leva FS; Festa C; D'Amore C; De Marino S; Renga B; D'Auria MV; Novellino E; Limongelli V; Zampella A; Fiorucci S
    J Med Chem; 2013 Jun; 56(11):4701-17. PubMed ID: 23656455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Structural Optimization of Dual FXR/PPARδ Activators.
    Schierle S; Neumann S; Heitel P; Willems S; Kaiser A; Pollinger J; Merk D
    J Med Chem; 2020 Aug; 63(15):8369-8379. PubMed ID: 32687365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryptochinones from Cryptocarya chinensis act as farnesoid X receptor agonists.
    Lin HR; Chou TH; Huang DW; Chen IS
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4181-6. PubMed ID: 25127166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.